bexagliflozin + probenecid

bexagliflozin + probenecid is a hypothetical combination of two small molecule drugs: bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and probenecid, a uricosuric agent that inhibits renal tubular reabsorption of uric acid and organic anion transporters. Bexagliflozin lowers blood glucose by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing its excretion in urine. Probenecid inhibits renal organic anion transporters such as OAT1 and OAT3, reducing uric acid reabsorption and increasing its excretion, and is also known to affect the pharmacokinetics of other drugs excreted via renal tubules. This combination is not marketed as a fixed-dose product; evidence indicates no clinically meaningful pharmacokinetic interaction between the two drugs. Both drugs are approved individually for their respective indications (type 2 diabetes mellitus for bexagliflozin, gout and as an adjunct in some antibiotic therapies for probenecid)[2][4][6].